News Releases

Date Title and Summary View
November 12, 2018
– Enlarged Phase 2 Study to Begin in 2018 for Potential Acute Treatment of Hereditary Angioedema; Data Expected in Late 2019 – – Food Effect Study Indicates No Dosing Limitations from Food and Confirms Rapid Uptake and High Exposure – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov....
Additional Formats
November 6, 2018
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 6, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a...
Additional Formats
September 25, 2018
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 25, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...
Additional Formats
September 14, 2018
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- – KVD900 Phase 2 On Track to Begin in 2018 for Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema – – Intravitreal Diabetic Macular Edema Candidate KVD001 Enrollment On Track with Data Expected in H2 2019 –...
Additional Formats
September 10, 2018
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 10, 2018-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the closing of its...
Additional Formats
September 6, 2018

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 6, 2018-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the pricing of its

...
Additional Formats
September 5, 2018

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 5, 2018-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, announced today that it intends to offer

...
Additional Formats
August 7, 2018

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug. 7, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a

...
Additional Formats
July 31, 2018

– KVD900 Selected to Advance to Phase 2 as Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema (HAE) – – KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME) Enrollment Remains on Track with Data Expected in H2 2019 – – $14.6 Million

...
Additional Formats
May 31, 2018
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 31, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a...
Additional Formats
Displaying 1 - 10 of 17